文献速递妇科

晚期卵巢癌心膈角淋巴结切除术的可行性、安全性与临床结局

Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-09-06

本研究报告了2001年1月至2013年12月在本机构接受初次肿瘤细胞减灭术并心膈角淋巴结(CPLN)切除的54例IIIB-IV期高级别上皮性卵巢癌患者,评估其可行性、安全性及对临床结局的潜在影响。中位无进展生存期为17.2个月(95%CI 12.6-21.8),中位总生存期为70.1个月(95%CI 51.2-89.0)。作者认为在适当条件下该手术可行、安全且不延迟化疗,在部分患者中可能改善生存。

要点

  • 54例患者接受CPLN切除,51例(94.4%)淋巴结转移阳性。
  • 19例(35%)发生术后主要并发症,其中4例(7%)与手术相关。
  • 中位无进展生存期17.2个月(95%CI 12.6-21.8),中位总生存期70.1个月(95%CI 51.2-89.0)。

核心结论

  • 术前影像可识别增大的心膈角淋巴结(CPLN),可能提示转移。
  • CPLN切除可识别腹腔外病变、确诊IV期疾病并获得最佳肿瘤细胞减灭。
  • 在适当条件下该手术可行、安全且不延迟化疗;在部分患者中可能改善生存。

研究设计与样本

  • 本机构2001年1月至2013年12月接受初次肿瘤细胞减灭术(CRS)联合CPLN切除的IIIB-IV期高级别上皮性卵巢癌患者54例。
  • 收集临床与病理资料并进行统计学检验。

主要发现

  • 所有患者术前影像均显示CPLN增大,中位直径1.3cm(范围0.6-2.9)。
  • 中位年龄59岁(范围41-74);48例(88.9%)经膈肌切除,6例(11.1%)行电视辅助胸腔镜手术。
  • 中位切除淋巴结3枚(范围1-23),中位阳性淋巴结2枚(范围0-22);51/54(94.4%)淋巴结阳性。
  • 51例(94.4%)放置胸管,中位拔管时间4天(范围2-12);44例(81.4%)有腹膜癌病。
  • 19例(35%)发生术后主要并发症,其中4例(7%)与手术相关;中位至辅助化疗时间40天(范围19-205)。

临床怎么用

  • 原文未据此给出推荐;作者认为在适当条件下CPLN切除可行、安全且不延迟化疗,在部分患者中可能改善生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Surgical resection of enlarged cardiophrenic lymph nodes (CPLNs) in primary treatment of advanced ovarian cancer has not been widely studied. We report on a cohort of patients undergoing CPLN resection during primary cytoreductive surgery (CRS), examining its feasibility, safety, and potential impact on clinical outcomes. METHODS: We identified all patients undergoing primary CRS/CPLN resection for Stages IIIB-IV high-grade epithelial ovarian cancer at our institution from 1/2001-12/2013. Clinical and pathological data were collected. Statistical tests were performed. RESULTS: 54 patients underwent CPLN resection. All had enlarged CPLNs on preoperative imaging. Median diameter of an enlarged CPLN: 1.3cm (range 0.6-2.9). Median patient age: 59y (range 41-74). 48 (88.9%) underwent transdiaphragmatic resection; 6 (11.1%) underwent video-assisted thoracic surgery. A median of 3 nodes (range 1-23) were resected. A median of 2 nodes (range 0-22) were positive for metastasis. 51/54 (94.4%) had positive nodes. 51 (94.4%) had chest tube placement; median time to removal: 4d (range 2-12). 44 (81.4%) had peritoneal carcinomatosis. 19 (35%) experienced major postoperative complications; 4 of these (7%) were surgery-related. Median time to adjuvant chemotherapy: 40d (range 19-205). All patients were optimally cytoreduced, 30 (55.6%) without visible residual disease. Median progression-free survival: 17.2mos (95% CI 12.6-21.8); median overall survival: 70.1mos (95% CI 51.2-89.0). CONCLUSIONS: Enlarged CPLNs can be identified on preoperative imaging and may indicate metastases. Resection can identify extra-abdominal disease, confirm Stage IV disease, obtain optimal cytoreduction. In the proper setting it is feasible, safe, and does not delay chemotherapy. In select patients, it may improve survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cowan RA, Tseng J, Murthy V, et al. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 28888540. doi:10.1016/j.ygyno.2017.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。